Education
About Us
Working with TipRanks
Follow Us
CVRx (CVRX)
NASDAQ:CVRX
CVRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.87 - $18.55
Previous CloseN/A
Volume20.10K
Average Volume (3M)393.85K
Market Cap
$189.28M
Enterprise Value$257.65M
Total Cash (Recent Filing)$106.19M
Total Debt (Recent Filing)$7.09M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 08, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding26,036,032
10 Day Avg. Volume743,259
30 Day Avg. Volume393,853
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.34
Price to Cash Flow (P/CF)-10.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.00
Enterprise Value/Ebitda-4.33
Forecast
1Y Price Target
$16.83Price Target Upside159.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
CVRx News
PremiumCompany Announcements
CVRx’s Earnings Call: Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Company Growth StrategyCVRx continues to execute against its 2025 priorities to build a world-class sales force, develop high-volume Barostim centers of excellence, and address adoption barriers.
Market PotentialThe company is seen as offering an attractive buying opportunity into a high-growth/high-GM medical device company fulfilling an unmet need in a $2.2B TAM.
Bears Say
Revenue ShortfallPreliminary Q1 revenue was short of expectations on a slower ramp-up from new reps and seasonal procedure softness.
Salesforce ChallengesSales force adjustments made in Q1/25 are expected to negatively impact results for at least the next few quarters as sales reps typically require 6-12 months to become productive.
Stock ValuationThe price target is decreased from $23 to $18, reflecting a less favorable valuation based on updated market conditions and company performance expectations.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $5.87 and its highest was $18.55 in the past 12 months.
What is CVRx’s market cap?
CVRx’s market cap is $189.28M.
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is May 08, 2025 which is in 26 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on Feb 04, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.375 by -$0.055.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -0.57.
How many shares outstanding does CVRx have?
CVRx has 26,036,032 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.375. Following the earnings report the stock price went down -7.2%.
Which hedge fund is a major shareholder of CVRx?
Currently, no hedge funds are holding shares in CVRX
---
CVRx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.83 (159.72% Upside)
$16.83 (159.72% Upside)
Blogger Sentiment
Bullish
CVRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 239.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.93%
12-Months-Change
Fundamentals
Return on Equity
-81.58%
Trailing 12-Months
Asset Growth
15.78%
Trailing 12-Months
Company Description
CVRx
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
---
CVRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and successful expansion in the U.S. market, alongside key reimbursement milestones and educational initiatives. However, challenges were noted in the European market, and there were increased operating expenses and interest expenses leading to a higher net loss.Read More>---
CVRX Stock 12 Month Forecast
Average Price Target
$16.83
▲(159.72% Upside)
Technical Analysis
Best Analysts Covering CVRX
1 Year
1 Year Success Rate
8/19 ratings generated profit
1 Year Average Return
+9.24%
reiterated a buy rating 4 days ago
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +9.24% per trade.
---